西班牙生物疗法治疗哮喘的成本效益 - Suppr | 超能文献

Cost-Effectiveness of Biologic Therapies in Asthma in Spain.

作者信息

Martinez-Moragon Eva

机构信息

Servicio de Neumologia, Hospital Universitario Dr Peset, Valencia, Spain.

出版信息

Arch Bronconeumol. 2023 Oct;59(10):621-622. doi: 10.1016/j.arbres.2023.05.007. Epub 2023 May 23.

DOI:10.1016/j.arbres.2023.05.007

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Cost-Effectiveness of Biologic Therapies in Asthma in Spain.西班牙生物疗法治疗哮喘的成本效益

Arch Bronconeumol. 2023 Oct;59(10):621-622. doi: 10.1016/j.arbres.2023.05.007. Epub 2023 May 23.

2

The use of biologic therapies for the management of pediatric asthma.生物疗法在小儿哮喘管理中的应用。

Pediatr Pulmonol. 2020 Mar;55(3):803-808. doi: 10.1002/ppul.24613. Epub 2019 Dec 27.

3

Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic?哮喘生物治疗的成本效益和比较效果：用生物制剂还是不用生物制剂？

Ann Allergy Asthma Immunol. 2019 Apr;122(4):367-372. doi: 10.1016/j.anai.2019.01.018. Epub 2019 Jan 28.

4

Editorial comment on "Cost-effectiveness of omalizumab for the treatment of severe pediatric allergic asthma-Results of a real-life study in Spain".关于“奥马珠单抗治疗重度儿童过敏性哮喘的成本效益——西班牙一项真实研究的结果”的编辑评论

Pediatr Allergy Immunol. 2023 Jul;34(7):e13980. doi: 10.1111/pai.13980.

5

[COVID-19, severe asthma, and biologic].[新型冠状病毒肺炎、重度哮喘与生物制剂]

Rev Mal Respir. 2021 Apr;38(4):423-426. doi: 10.1016/j.rmr.2021.03.002. Epub 2021 Mar 18.

6

The Long Road to Biologic Therapies for Asthma in Pediatric Patients.儿童哮喘生物疗法的漫长之路

Arch Bronconeumol (Engl Ed). 2021 Apr;57(4):249-250. doi: 10.1016/j.arbres.2020.08.003. Epub 2020 Sep 24.

7

Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations.生物哮喘治疗的成本效益：系统评价及对未来经济评估的建议。

Pharmacoeconomics. 2018 Aug;36(8):957-971. doi: 10.1007/s40273-018-0658-x.

8

Economic analysis of biological therapies for severe asthma treatment.重度哮喘治疗生物疗法的经济学分析

Farm Hosp. 2019 Nov 1;43(6):175-176. doi: 10.7399/fh.11342.

9

Real-life small airway outcomes in severe asthma patients receiving biologic therapies.接受生物疗法的重度哮喘患者的真实生活中小气道结局

J Allergy Clin Immunol Pract. 2021 Jul;9(7):2907-2909. doi: 10.1016/j.jaip.2021.01.029. Epub 2021 Feb 2.

10

Reduced COVID-19 Vaccine Response in Patients Treated with Biologic Therapies for Asthma.接受生物疗法治疗哮喘的患者中COVID-19疫苗反应降低。

Am J Respir Crit Care Med. 2022 May 15;205(10):1243-1245. doi: 10.1164/rccm.202111-2496LE.

引用本文的文献

1

Monoclonal antibodies in severe asthma: outcomes from real-world data.重度哮喘中的单克隆抗体：来自真实世界数据的结果

Front Med (Lausanne). 2025 Aug 11;12:1635688. doi: 10.3389/fmed.2025.1635688. eCollection 2025.

2

Utility of the Basophil Reactivity Test in the Clinical Management of People with Severe Uncontrolled Asthma.嗜碱性粒细胞反应性试验在重度未控制哮喘患者临床管理中的应用

J Asthma Allergy. 2025 Apr 7;18:519-528. doi: 10.2147/JAA.S505951. eCollection 2025.